HomeQuestion
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
1
3 Answers
Mednet Member
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
The FDA approved talazoparib plus enzalutamide for HRRm metastatic CRPC in June 2023. NCCN panel recommends talazoparib plus enzalutamide as a category 1 treatment option for patients with metastatic CRPC and a pathogenic mutation (germline and/or somatic) in one of certain HRR and other DNA repair ...
Mednet Member
Medical Oncology · The University of Texas Health Science Center at San Antonio
Not at this time until more data is released from the ongoing studies such as AMPLITUDE/TALAPRO-3 are published. There are risks of serious bone marrow toxicity such as bone marrow failure, leukemia, and myelodysplastic syndrome with PARPi. (1) Presumably this risk is dose-related and duration-relat...